In agreement with this, CREBBP mutations have been previously associated with a high incidence of relapse in ALL patients (Mullighan et al., 2011), whereas NF1 mutations do not seem to change overall survival in ALL (Huang et al., 2024). Here, CREBBP is linked to acute lymphoblastic leukemia.